A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →. With Grupo Argentino Oncología Torácica (GAOT) - Asociación Argentina Oncología Clínica (AAOC).
Phase
—
Status
Completed
Study type
Observational
Enrollment
70actual
Sites
1
Country
Argentina
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-26 | actual | When the study began enrolling |
| Primary completion | 2025-11-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-18 | actual | The whole study's end, after follow-up |
| First posted | 2025-08-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer (NSCLC)
Intervention
- Drug: Nivolumab + platinum-based chemotherapy — also filed as Opdivo, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Gemcitabine.
Primary outcome
what the primary-completion date above is the date OFRate of pathological complete response (pCR) post-surgery
measured Up to 1 year
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed